Placebo effects and participant heterogeneity in clinical trials of autism spectrum disorder

Eva Loth¹

Affiliations

¹ Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK. Electronic address: eva.loth@kcl.ac.uk.

Comment

Eva Loth. Lancet Psychiatry. 2022 Mar.

. 2022 Mar;9(3):184-185.

doi: 10.1016/S2215-0366(21)00504-6. Epub 2022 Feb 10.

Eva Loth¹

¹ Department of Forensic and Neurodevelopmental Sciences, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, UK. Electronic address: eva.loth@kcl.ac.uk.

No abstract available

Conflict of interest statement

I declare no competing interests.

Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E, Anagnostou E. Jacob S, et al. Lancet Psychiatry. 2022 Mar;9(3):199-210. doi: 10.1016/S2215-0366(21)00429-6. Epub 2022 Feb 10. Lancet Psychiatry. 2022. PMID: 35151410 Clinical Trial.